DASON COVID-19 Weekly Treatment Literature Update 11/13/2020
Prepared by: Angelina Davis, PharmD, MS, April Dyer, PharmD, MBA, MSCR, Elizabeth Dodds Ashley, PharmD, MHS, Melissa Johnson, PharmD, MHS, S. Shaefer Spires, MD, Travis Jones, PharmD

The following summarizes key literature pertaining to treatment of COVID-19 during the past week.
*Note: some of the data discussed below may be in pre-print form that has not yet been peer-reviewed. We have noted some discrepancies in some of this data, and final printed versions may ultimately differ from what is shown here. We will update as soon as possible; caution is advised when interpreting this literature.

NIH Guideline Updates
The NIH Treatment Guidelines were not updated in the past week.

Therapeutic/Regulatory Information
Big news this week was the EUA issued for the Eli Lilly Monoclonal antibody bamlanivimab.
Here are the links to the:
EUA press release
EUA letter
Fact sheet for providers
Fact sheet for patients/caregivers
Allocation process
Current state allocations
Additionally, CMS is covering cost of care for the monoclonal in Medicare patients.
IDSA/HIMA put out a joint statement on the EUA
Please reach out to your DASON liaison to help you work through local questions and concerns about use of this agent.

Other big news was announced about the Pfizer vaccine. This was in the form of a press release. Below are some thoughts on the presented data by our colleague Jason Stout, MD:
• Their phase 3 mRNA vaccine has enrolled 43,538 participants
• Of those, 38,955 have received the full two-dose vaccine series as of 11/8/2020
• This interim analysis was preplanned to look at the data after a minimum of 62 COVID cases (endpoints) were detected
• There were actually 94 confirmed COVID cases among trial participants at the time of the analysis
• No actual numbers of cases in each study arm were provided, but the vaccine efficacy in preventing COVID at 7 days after the last dose (28 days after starting the series) was "over 90%"
• No safety concerns were raised
• The study is planned to stop (final analysis) after 164 COVID cases have been accrued, so they are about 60% of the way there
New Literature This Week
There have been no major COVID-related publications this week that would alter clinical practice.

Treatment Summary Tables
NIH Treatment Guidelines Summary:

The remdesivir summary table with the information of published studies to date can be found at this link:

The hydroxychloroquine summary table is available at this link:

The tocilizumab summary table with the information of published studies to date can be found at this link

The convalescent plasma summary table is available at this link:
All FAQs available here: https://dason.medicine.duke.edu/covid-19-novel-coronavirus-resources